Boehringer's survodutide meets cardiovascular safety bar in Phase III

Boehringer Ingelheim has reported that survodutide, its investigational glucagon/GLP-1 dual agonist, met the primary endpoint of its Phase III SYNCHRONIZE-CVOT cardiovascular outcomes trial, demonstrating non-inferiority to placebo on a composite five-point major adverse cardiovascular event (5P-MACE) measure. The results were presented at the American Heart Association Scientific Sessions in Chicago on 9 November and published simultaneously in The Lancet.

The double-blind, placebo-controlled study enrolled 5,530 adults living with obesity or overweight who also had established cardiovascular disease, chronic kidney disease, or at least two weight-related risk factors for cardiovascular disease. Participants received weekly subcutaneous injections of survodutide at either 3.6 mg or 6.0 mg, or placebo, for 72 weeks. The hazard ratio for 5P-MACE using the treatment-regimen estimand was 0.89 (95% CI: 0.67–1.18; p<0.0001 for non-inferiority), indicating no increased cardiovascular risk attributable to the drug.

Cardiometabolic benefits beyond weight loss

Secondary endpoints add clinical weight to the cardiovascular safety readout. Survodutide reduced systolic blood pressure by up to 6.68 mmHg at 72 weeks against 1.76 mmHg in the placebo arm (p=0.0001). Waist circumference, a surrogate for visceral adiposity and cardiometabolic risk, fell by up to 11.96 cm versus 2.74 cm with placebo. Body weight declined by up to 13.7% in the survodutide arms, including participants with type 2 diabetes, compared with 2.0% in the control group. Significant reductions were also observed in high-sensitivity C-reactive protein and triglycerides, both established cardiovascular risk biomarkers.

Principal investigator Biykem Bozkurt said: "We are looking at novel therapeutic approaches that do not merely reduce body weight but can also improve metabolic dysfunction while maintaining cardiovascular safety."

Tolerability remains a known challenge for GLP-1-based agents. Gastrointestinal adverse events were the most commonly reported, with treatment discontinuation rates of 19.3% and 20.8% at the 3.6 mg and 6.0 mg doses respectively, compared with 1.9% in the placebo group. Boehringer acknowledges that the initial protocol's limited flexibility for dose titration contributed to discontinuations that might have been avoidable, and says upcoming Phase IIIb studies will incorporate more patient-centred titration strategies.

Regulatory and competitive context

SYNCHRONIZE-CVOT is the first completed cardiovascular outcomes trial for a glucagon/GLP-1 dual agonist, giving Boehringer a dataset its competitors in the dual-agonist class have not yet produced. Eli Lilly's tirzepatide, a GIP/GLP-1 dual agonist, generated positive cardiovascular outcomes data in heart-failure patients earlier this year, but the glucagon receptor mechanism in survodutide is designed to offer distinct advantages in energy expenditure and liver metabolism compared with GIP-based approaches.

Boehringer said it is preparing regulatory submissions for survodutide in obesity on the basis of the full SYNCHRONIZE programme. For MASH, survodutide already holds FDA Breakthrough Therapy designation and EMA PRIME status, and two further Phase III trials, LIVERAGE and LIVERAGE-Cirrhosis, are ongoing. The company licenses survodutide from Zealand Pharma and retains sole responsibility for global development and commercialisation.

The GLP-1-based obesity market has expanded rapidly since the approvals of semaglutide and tirzepatide, with cardiovascular outcome data increasingly a commercial prerequisite. A favourable cardiovascular safety profile is now effectively a table-stakes requirement for any new entrant seeking reimbursement in markets such as the United States and the European Union, where payers and guideline bodies look for MACE data before broadening access. Survodutide's dataset, once reviewed by regulators, could differentiate it in a crowded field if its broader metabolic effects prove clinically meaningful in real-world populations.